| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
167 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
53 |
| Net Income (TTM) (Millions $) |
-208 |
| Cash Flow (TTM) (Millions $) |
-9 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Epizyme Inc. is a biopharmaceutical company based in the United States. The company focuses on the discovery, development, and commercialization of novel personalized therapeutics for patients with genetically defined cancers. Epizyme's approach involves targeting specific gene mutations and enzymatic pathways to develop innovative therapies. They create small molecule inhibitors designed to modulate the activity of these enzymes, potentially leading to the suppression or elimination of cancer cells. The goal is to provide patients with more effective and individualized treatment options. Epizyme has multiple drug candidates in its pipeline and collaborates with other pharmaceutical companies to advance its research and development efforts.
Company Address: 400 Technology Square, 4th Floor Cambridge 2139 MA
Company Phone Number: 229-5872 Stock Exchange / Ticker: NASDAQ EPZM
|
%
5.06%